Chinook Therapeutics Inc
NASDAQ:KDNY
Intrinsic Value
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. [ Read More ]
The intrinsic value of one KDNY stock under the Base Case scenario is 17.22 USD. Compared to the current market price of 40.39 USD, Chinook Therapeutics Inc is Overvalued by 57%.
Valuation Backtest
Chinook Therapeutics Inc
Run backtest to discover the historical profit from buying and selling KDNY stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Chinook Therapeutics Inc
Current Assets | 305.4m |
Cash & Short-Term Investments | 297.2m |
Receivables | 3.1m |
Other Current Assets | 5.2m |
Non-Current Assets | 183.4m |
Long-Term Investments | 48m |
PP&E | 59.1m |
Intangibles | 60.1m |
Other Non-Current Assets | 16.2m |
Current Liabilities | 52.5m |
Accounts Payable | 16.4m |
Accrued Liabilities | 33.6m |
Other Current Liabilities | 2.5m |
Non-Current Liabilities | 79.3m |
Other Non-Current Liabilities | 79.3m |
Earnings Waterfall
Chinook Therapeutics Inc
Revenue
|
5.8m
USD
|
Operating Expenses
|
-257.5m
USD
|
Operating Income
|
-251.6m
USD
|
Other Expenses
|
6m
USD
|
Net Income
|
-245.7m
USD
|
Free Cash Flow Analysis
Chinook Therapeutics Inc
KDNY Profitability Score
Profitability Due Diligence
Chinook Therapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Chinook Therapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
KDNY Solvency Score
Solvency Due Diligence
Chinook Therapeutics Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
Chinook Therapeutics Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KDNY Price Targets Summary
Chinook Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for KDNY is 40 USD .
Ownership
KDNY Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
KDNY Price
Chinook Therapeutics Inc
Average Annual Return | 35.15% |
Standard Deviation of Annual Returns | 123.1% |
Max Drawdown | -79% |
Market Capitalization | 2.7B USD |
Shares Outstanding | 67 049 500 |
Percentage of Shares Shorted | 4.97% |
KDNY News
Last Important Events
Chinook Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Chinook Therapeutics Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company is headquartered in Seattle, Washington and currently employs 138 full-time employees. The company went IPO on 2015-04-15. The firm is focused on discovering, developing and commercializing medicines for kidney diseases. Its lead product candidate is atrasentan, which is a selective endothelin A receptor antagonist that is developed for the treatment of proteinuric glomerular diseases. The Company’s second product candidate, BION-1301, is an investigational humanized IgG4 monoclonal antibody that blocks APRIL, a soluble factor that is implicated in IgAN and other indications, from binding to its receptors. Its third clinical development candidate is CHK-336, a liver-targeted oral small molecule lactate dehydrogenase (LDHA), inhibitor, which is developed for the treatment of primary hyperoxaluria (PH), as well as secondary hyperoxaluria and idiopathic kidney stone formation. The company is conducting a Phase I/II clinical trial of BION-1301.
Contact
IPO
Employees
Officers
The intrinsic value of one KDNY stock under the Base Case scenario is 17.22 USD.
Compared to the current market price of 40.39 USD, Chinook Therapeutics Inc is Overvalued by 57%.